HPHolly Price

Holly Price

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Holly Price has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Defocus Incorporated Multiple Segments (DIMS) spectacle lenses in UK children: Outcomes from a 2‐year multi‐site interventional trial

    by Sara McCullough, Holly Barr, Jane Fulton, Susie Jones, Nicola Logan, Manbir Nagra, Shahina Pardhan, Patrick Richardson, Kathryn Saunders, Yasmin Whayeb, et al.

    Introduction: Myopia is a growing public health concern with long‐term risks for visual impairment. While Defocus Incorporated Multiple Segments (DIMS) spectacle lenses have proven efficacy in Chinese children, evidence from Western populations remains limited. This multi‐site interventional study evaluates the effectiveness of DIMS lenses in slowing myopia progression and their visual acceptability and tolerability among UK children. Methods: Children aged 5–15 years with cycloplegic spherical equivalent refraction (SER) of −0.50 to −8.50 D, anisometropia ≤1.50 D and astigmatism ≤2.50 D were recruited. All participants were prescribed DIMS spectacle lenses. SER (cycloplegic autorefraction) and axial length (AL, IOLMaster) were measured at baseline and at 6‐monthly intervals for 24 months. Measured axial elongation was compared to expected eye growth in age‐ and ethnicity‐matched untreated myopes from published meta‐analyses. Visual function (distance/near visual acuity, stereoacuity, accommodative lag and ocular posture) and visual symptoms (participant questionnaire) were also assessed. Results: A total of 108 participants completed the study to 2 years (baseline age 10.2 ± 2.2 years). Model‐adjusted mean (SE) changes in SER and AL change were −0.35 ± 0.04 D and 0.17 ± 0.01 mm at 12 months and −0.57 ± 0.05 D and 0.30 ± 0.03 mm at 24 months. Compared to expected untreated myopic progression, children wearing DIMS spectacle lenses showed 0.27 ± 0.20 mm (mean ± SD) less axial elongation over 24 months, with 91% exhibiting slower than average untreated myopic eye growth. Measures of visual function were comparable through DIMS and single‐vision spectacle lenses. Fifty‐seven percent of participants reported no visual symptoms within the first week, and on average, visual symptoms were ‘never’ or ‘seldom’ experienced by participants after 12 and 24 months of DIMS wear. Conclusions: This study provides robust and novel evidence demonstrating that DIMS spectacle lenses provide meaningful slowing of axial elongation among UK children. Minimal visual symptoms and preserved visual function throughout lens wear support their clinical viability and real‐world applicability for myopia management in diverse populations.


  • Open Access

    Erratum. Global Estimates on the Number of People Blind or Visually Impaired by Diabetic Retinopathy: A Meta-analysis From 1990–2010. Diabetes Care 2016;39:1643–1649

    by Janet L. Leasher, Rupert R.A. Bourne, Seth R. Flaxman, Jost B. Jonas, Jill Keeffe, Novin Naidoo, Konrad Pesudovs, Holly Price, Richard A. White, Tien Y. Wong, et al.

    In the article listed above, there is an error in Table 1. The value for “Number …


  • Top Cited Papers
    Open Access

    Global Estimates on the Number of People Blind or Visually Impaired by Diabetic Retinopathy: A Meta-analysis From 1990 to 2010

    by Janet L. Leasher, Rupert R.A. Bourne, Seth R. Flaxman, Jost B. Jonas, Jill Keeffe, Kovin Naidoo, Konrad Pesudovs, Holly Price, Richard A. White, Tien Y. Wong, et al.

    OBJECTIVE: To estimate global and regional trends from 1990 to 2010 of the prevalence and number of persons visually impaired specifically by diabetic retinopathy (DR), as a complication of the precipitous trends in global diabetes, is fundamental for health planning purposes. RESEARCH DESIGN AND METHODS: The meta-analysis of published population studies from 1990 to 2012 for the Global Burden of Disease Study 2010 (GBD) yielded estimated global regional trends in DR among other causes of moderate and severe vision impairment (MSVI; presenting visual acuity <6/18, ≥3/60) and blindness (presenting visual acuity <3/60). RESULTS: Globally in 2010, out of overall 32.4 million blind and 191 million visually impaired people, 0.8 million were blind and 3.7 million were visually impaired because of DR, with an alarming increase of 27% and 64%, respectively, spanning the two decades from 1990 to 2010. DR accounted for 2.6% of all blindness in 2010 and 1.9% of all MSVI worldwide, increasing from 2.1% and 1.3%, respectively, in 1990. These figures were lower in regions with younger populations (4%). CONCLUSIONS: The number of persons with visual impairment due to DR worldwide is rising and represents an increasing proportion of all blindness/MSVI causes. Age-standardized prevalence of DR-related blindness/MSVI was higher in sub-Saharan Africa and South Asia. One out of 39 blind people had blindness due to DR, and 1 out of 52 visually impaired people had visual impairment due to DR.


  • Prevalence and causes of vision loss in sub-Saharan Africa: 1990–2010

    by Kovin Naidoo, Stephen Gichuhi, María-Gloria Basáñez, Seth R Flaxman, Jost B Jonas, Jill Keeffe, Janet L Leasher, Konrad Pesudovs, Holly Price, Jennifer L Smith, et al.

    Aim To estimate the magnitude, temporal trends and subregional variation in the prevalence of blindness, and moderate/severe vision impairment (MSVI) in sub-Saharan Africa. Methods A systematic review was conducted of published and unpublished population-based surveys as part of the Global Burden of Disease, Risk Factors and Injuries Study 2010. The prevalence of blindness and vision impairment by country and subregion was estimated. Results In sub-Saharan Africa, 52 studies satisfied the inclusion criteria. The estimated age-standardised prevalence of blindness decreased by 32% from 1.9% (95% CI 1.5% to 2.2%) in 1990 to 1.3% (95% CI 1.1% to 1.5%) in 2010 and MSVI by 25% from 5.3% (95% CI 0.2% to 0.3%) to 4.0% (95% CI 0.2% to 0.3%) over that time. However, there was a 16% increase in the absolute numbers with blindness and a 28% increase in those with MSVI. The major causes of blindness in 2010 were; cataract 35%, other/unidentified causes 33.1%, refractive error 13.2%, macular degeneration 6.3%, trachoma 5.2%, glaucoma 4.4% and diabetic retinopathy 2.8%. In 2010, age-standardised prevalence of MSVI in Africa was 3.8% (95% CI 3.1% to 4.7%) for men and 4.2% (95% CI 3.6% to 5.3%) for women with subregional variations from 4.1% (95% CI 3.3% to 5.4%) in West Africa to 2.0% (95% CI 1.5% to 3.3%) in southern Africa for men; and 4.7% (95% CI 3.9% to 6.0%) in West Africa to 2.3% (95% CI 1.7% to 3.8%) in southern Africa for women. Conclusions The age-standardised prevalence of blindness and MSVI decreased substantially from 1990 to 2010, although there was a moderate increase in the absolute numbers with blindness or MSVI. Significant subregional and gender disparities exist.